- Home
- NIE vs CVAC Comparison
NIE vs CVAC Comparison
Compare NIE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- CVAC
- Stock Information
- Founded
- NIE 2007
- CVAC 2000
- Country
- NIE United States
- CVAC Germany
- Employees
- NIE N/A
- CVAC N/A
- Industry
- NIE Investment Managers
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- CVAC Health Care
- Exchange
- NIE Nasdaq
- CVAC Nasdaq
- Market Cap
- NIE 697.4M
- CVAC 818.8M
- IPO Year
- NIE N/A
- CVAC 2020
- Fundamental
- Price
- NIE $22.31
- CVAC $3.47
- Analyst Decision
- NIE
- CVAC Strong Buy
- Analyst Count
- NIE 0
- CVAC 2
- Target Price
- NIE N/A
- CVAC $14.00
- AVG Volume (30 Days)
- NIE 70.5K
- CVAC 535.9K
- Earning Date
- NIE 01-01-0001
- CVAC 05-22-2025
- Dividend Yield
- NIE 9.04%
- CVAC N/A
- EPS Growth
- NIE N/A
- CVAC N/A
- EPS
- NIE N/A
- CVAC 0.75
- Revenue
- NIE N/A
- CVAC $554,073,921.00
- Revenue This Year
- NIE N/A
- CVAC N/A
- Revenue Next Year
- NIE N/A
- CVAC $38.07
- P/E Ratio
- NIE N/A
- CVAC $4.65
- Revenue Growth
- NIE N/A
- CVAC 895.54
- 52 Week Low
- NIE $18.61
- CVAC $2.22
- 52 Week High
- NIE $22.47
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- NIE 57.69
- CVAC 56.52
- Support Level
- NIE $21.92
- CVAC $3.26
- Resistance Level
- NIE $22.50
- CVAC $3.63
- Average True Range (ATR)
- NIE 0.32
- CVAC 0.21
- MACD
- NIE 0.15
- CVAC 0.01
- Stochastic Oscillator
- NIE 90.71
- CVAC 51.83
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.